NCT05562297 is a Phase 2 clinical trial of sintilimab in Pancreatic Cancer, Stage IB, sponsored by Shanghai Zhongshan Hospital.

Who is sponsoring NCT05562297?

NCT05562297 is sponsored by Shanghai Zhongshan Hospital.

What drugs are being tested in NCT05562297?

Interventions in NCT05562297: sintilimab, nab-paclitaxel, gemcitabine.

What condition does NCT05562297 study?

NCT05562297 studies Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA, Pancreatic Cancer, Stage IIB, Pancreatic Cancer Stage III.

Is NCT05562297 still recruiting?

NCT05562297 is currently not yet recruiting. Last updated 22 January 2025.

Last reviewed 2025-01-22 · How we verify

NCT05562297

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

Not yet recruiting Phase 2 Last updated 22 January 2025

What this trial tests

Phase 2 trial testing sintilimab in Pancreatic Cancer, Stage IB in 50 participants. Not yet recruiting.

Timeline

20 March 2025

Primary endpoint
1 October 2027

1 October 2028

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	20 March 2025
Primary completion	1 October 2027
Estimated completion	1 October 2028
Sites	1 location across China

Drugs / interventions tested

sintilimab — full drug profile →
nab-paclitaxel (nab-paclitaxel) — full drug profile →
gemcitabine (gemcitabine) — full drug profile →

Conditions studied

Pancreatic Cancer, Stage IB — all drugs for Pancreatic Cancer, Stage IB →
Pancreatic Cancer, Stage IIA — all drugs for Pancreatic Cancer, Stage IIA →
Pancreatic Cancer, Stage IIB — all drugs for Pancreatic Cancer, Stage IIB →
Pancreatic Cancer Stage III — all drugs for Pancreatic Cancer Stage III →

Sponsor

Shanghai Zhongshan Hospital

Who can join

Adults 18 to 75, any sex, with Pancreatic Cancer, Stage IB or Pancreatic Cancer, Stage IIA. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research is to investigate the activity and safety of the combination of gemcitabine plus nab-paclitaxel and sintilimab as neoadjuvant therapy in treating patients with resectable and borderline resectable pancreatic cancer. The drugs involved in this study are: * Sintilimab * Nab-paclitaxel * Gemcitabine

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results.
Chick RC, Gunderson AJ, Rahman S, Cloyd JM. · · 2023 · cited 16× · PMID 37568782 · DOI 10.3390/cancers15153967
The Road Ahead in Pancreatic Cancer: Emerging Trends and Therapeutic Prospects.
Do CTP, Prochnau JY, Dominguez A, Wang P, et al · · 2024 · cited 7× · PMID 39335494 · DOI 10.3390/biomedicines12091979
Crosstalk between the tumor immune microenvironment and metabolic reprogramming in pancreatic cancer: new frontiers in immunotherapy.
Shi J, Cui X, Wang J, Liu G, et al · · 2025 · cited 4× · PMID 40356913 · DOI 10.3389/fimmu.2025.1564603
Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma: Aligning Guideline Recommendations with Real-World Evidence.
Cammarata R, Catamerò A, La Vaccara V, Coppola R, et al · · 2025 · PMID 41008927 · DOI 10.3390/cancers17183085

Verify or expand the search:

Other trials of sintilimab

Trials testing the same drug.

NCT07487662 — TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcin · Phase 2 · not yet recruiting
NCT07018063 — Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer · Phase 2 · not yet recruiting
NCT07007767 — Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies） · Phase 2 · not yet recruiting
NCT06584032 — Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer · Phase 3 · recruiting
NCT06487715 — Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With · Phase 2 · unknown

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05562297 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 22 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05562297.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing